Comparing Remodulin vs Tyvaso DPI
| Remodulin (treprostinil) | Tyvaso DPI (treprostinil) |
|
|---|
| Remodulin (treprostinil) | Tyvaso DPI (treprostinil) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Pulmonary Arterial Hypertension. Remodulin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Pulmonary Arterial Hypertension. Tyvaso DPI may also be used for purposes not listed in this medication guide. |
||||||||
| More about Remodulin (treprostinil) | More about Tyvaso DPI (treprostinil) | ||||||||
| Ratings & Reviews | |||||||||
|
Remodulin has an average rating of 6.6 out of 10 from a total of 7 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 14% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Remodulin side effects |
View all Tyvaso DPI side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Remodulin prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
| Other treprostinil brands include: Orenitram, Tyvaso, Tyvaso DPI, Yutrepia | Other treprostinil brands include: Orenitram, Remodulin, Tyvaso, Yutrepia | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
4 hours |
4 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category B
No proven risk in humans
Treprostinil (Remodulin, Tyvaso)
Category C
Risk cannot be ruled out
Treprostinil Oral (Orenitram) See the full pregnancy warnings document. |
Category B
No proven risk in humans
Treprostinil (Remodulin, Tyvaso)
Category C
Risk cannot be ruled out
Treprostinil Oral (Orenitram) See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 328 drugs are known to interact with Remodulin:
|
A total of 328 drugs are known to interact with Tyvaso DPI:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
N/A |
May 23, 2022 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.